Skip to content

Pancreatic Cancer Health Center

Font Size

Recurrent and Progressive Pancreatic Neuroendocrine Tumors

    There is no established therapy for pancreatic neuroendocrine tumors that recur or progress after prior therapy.[1] Deciding on further treatment depends on many factors, including:

    • The specific cancer.
    • Prior treatment.
    • Site of recurrence.
    • Individual patient considerations.

    Attempts at re-resection of local tumors that have recurred or metastatic lesions may offer palliation, when technically feasible. Intra-arterial chemotherapy is a consideration for patients with liver metastases. Patients with hepatic-dominant disease and substantial symptoms caused by tumor bulk or hormone-release syndromes may benefit from continuous-infusion intra-arterial chemotherapy or procedures that reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion with embolization or with chemoembolization).[2,3,4,5,6,7] Such treatment may also be combined with systemic chemotherapy. A variety of systemic agents have shown biologic or palliative activity,[1,8] including:

    Recommended Related to Pancreatic Cancer

    Understanding Pancreatic Cancer -- Diagnosis and Treatment

    To diagnose pancreatic cancer, a doctor will order certain imaging tests, such as a pancreatic ultrasound or a CT scan of the abdomen. Endoscopic ultrasonography (EUS) uses an ultrasound device connected to the end of a small flexible tube that is inserted into the mouth and is about 85% to 90% accurate in diagnosing pancreatic cancer. If necessary, endoscopic retrograde cholangiopancreatography (ERCP) is used. With ERCP, detailed images are obtained by inserting an endoscope into the mouth to the...

    Read the Understanding Pancreatic Cancer -- Diagnosis and Treatment article > >

    • Somatostatin analogs.
    • Radiolabeled somatostatin analogs.[9,10,11]
    • Tyrosine kinase inhibitors (e.g., sunitinib).
    • Temozolomide.
    • Vascular endothelial growth factor pathway inhibitors.
    • Mammalian target of rapamycin inhibitors (e.g., everolimus).

    Current Clinical Trials

    Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent islet cell carcinoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

    General information about clinical trials is also available from the NCI Web site.

    References:

    1. Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011.
    2. Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005.
    3. Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008.
    4. King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008.
    5. Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001.
    6. Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev (2): CD007060, 2009.
    7. Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev (1): CD007118, 2009.
    8. Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010.
    9. Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005.
    10. Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008.
    11. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010.

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

      WebMD Public Information from the National Cancer Institute

      Last Updated: February 25, 2014
      This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
      1

      Today on WebMD

      human pancreas
      Do you know what they are?
      man with a doctor
      Our health check will steer you in the right direction.
       
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Lung cancer xray
      See it in pictures, plus read the facts.
       
      Integrative Medicine Cancer Quiz
      QUIZ
      Patrick Swayzes Widow Healing From Loss
      FEATURE
       
      Pets Improve Your Health
      SLIDESHOW
      Resolved To Quit Smoking
      SLIDESHOW
       

      WebMD Special Sections